Myocardial perfusion scintigraphy: Past, present and future

British Journal of Radiology

Volumn 84, Issue SPEC. ISSUE 3, 2011, Pages

  Notghi, A ^a   Low, C S ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; DIPYRIDAMOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; SODIUM IODIDE; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; COMPUTER PROGRAM; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; MYOCARDIAL PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX PAIN; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; IMAGE PROCESSING; INSTRUMENTATION; METHODOLOGY; NUCLEAR MEDICINE; PROGNOSIS; REVIEW; SCINTISCANNING;

CORONARY ARTERY DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SOFTWARE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84865660737     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/14625142     Document Type: Article

References (54)

1. Vitola JV, Shaw LJ, Allam AH, Orellana P, Peix A, Ellmann A, et al. Assessing the need for nuclear cardiology and other advanced cardiac imaging modalities in the developing world. J Nucl Cardiol 2009;16:956-61.
2. National Institute for Health and Clinical Excellence. Chest pain of recent onset: assessment and diagnosis of recent onset. NICE Clinical Guideline 95. London, UK: NICE, 2010.
3. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarctions. Circulation 1998;97:535-43.
4. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission com-puted tomography. Circulation 2003;107:2900-7.
5. Underwood SR, Godman B, Salyani S, Ogle J, Ell PJ. Economics of myocardial perfusion imaging in Europe: the EMPIRE study. Eur Heart J 1999;20:157-66.
6. Anagnostopoulos C, Harbinson M, Kelion A, Kundley K, Loong CY, Notghi, et al. Procedure guidelines for radionu-clide myocardial perfusion imaging. Heart 2004;90:i1-i10.
7. Hesse B, Tägil K, Cuocolo A, Anagnostopoulos C, Bardiés M, Bax J, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:855-97
8. Strauss HW, Miller DD, Wittry MD, Cerqueira MD, Garcia EV, Iskandrian AS, et al. Procedure guideline for myocar-dial perfusion imaging 3.3. J Nucl Med Tech 2008;36: 155-61.
9. Garcia EV. SPECT attenuation correction: an essential tool to realize nuclear cardiology's manifest destiny. J Nucl Cardiol 2007;14:16-24.
10. Lebowitz E, Greene MV, Fairchild R, Bradley-Moore PR, Atkins HL, Ansari AN, et al. Thallium-201 for medical use. I. J Nucl Med 1975;16:151-5.
11. Beller GA, Watson DD, Ackell P, Pohost GM. Time course of thallium-201 redistribution after transient myocardial ischemia. Circulation 1980;61:791-7.
12. Dahlber ST. Assessment of myocardial perfusion with Tc-99m: Image is everything. J Nucl Cardiol 2009;16:493-6.
13. Watson DD, Campbell NP, Read EK. Spatial and temporal quantification of plane thallium myocardial images. J Nucl Med 1981;22:577-84.
14. Garcia E, Maddahi J, Berman D, Waxman A. Space/time quantification of thallium-201 myocardial scintigraphy. J Nucl Med 1981;22:309-17
15. Iskandrian AS, Verani MS, Heo JY. Pharmacologic stress testing: mechanism of action, haemodynamic responses, and results in detection of coronary disease. J Nucl Cardiol 1994;1:94-111.
16. Sharir T, Slomka PJ, Berman DS. Solid-state SPECT technology: fast and furious. J Nucl Cardiol 2010;17:890-6.
17. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
18. Gaemperli O, Kaufmann P. 2006 Image of the Year: focus on cardiac SPECT/CT. J Nucl Med 2006;47:14N.
19. Di Carli MF, Dorbala S, Meserve J, El-Fakhri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. J Nucl Med 2007;48:783-93.
20. Garcia EV, Cooke CD, Folks RD, Santana CA, Krawczynska EG, De Braal L, et al. Diagnostic performance of an expert system for the interpretation of myocardial perfusion SPECT studies. J Nucl Med 2001;42:1185-91.
21. Sciagrà R. The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene. Eur J Nucl Med Mol Imaging 2007;34:1107-22.
22. Schindler TH, Quercioli A. Left ventricular dyssynchrony assessment by phase analysis from gated myocardial perfusion SPECT: moving beyond conventional criteria. Heart 2011;97:4-5.
23. Chen J, Boogers MM, Bax JJ, Soman P, Garcia EV. The use of nuclear imaging for cardiac resynchronisation therapy. Curr Cardiol Rep 2010;12:185-91.
24. Boogers MJ, Chen J, van Bommel RJ, Borleffs CJW, Dibbets-Schneider P, van der Hiel B, et al. Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT. Eur J Nucl Med Mol Imaging 2011;38:230-8.
25. Uebleis C, Ulbrich M, Tegtmeyer R, Schuessler F, Haserueck N, Siebermair J, et al. Electrocardiogram-gated 18F-FDG PET/CT hybrid imaging in patients with unsa-tisfactory response to cardiac resynchronisation therapy: initial clinical results. J Nucl Med 2011;52:67-71.
26. Bilchick KC. Single photon emission computed tomography (SPECT) techniques for resynchronisation: phase analysis and equilibrium radionuclide angiocardiography. J Nucl Cardiol 2011;18:16-20.
27. Liu Z, Chen L, Liu S, Barber C, Stevenson GD, Furenlid LR, et al. Kinetic characterization of a novel cationic 99mTc(I)-tricarbonyl complex, 99mTc-15C5-PNP, for myocardial perfusion imaging. J Nucl Cardiol 2010;17:858-67.
28. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75-94.
29. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-m IBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
30. Flotats A, Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004;11:587-602.
31. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol 2008;15:442-55.
32. Goodman MM, Kirsch G, Knapp FF Jr. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-sub-stituted alpha-and beta-methyl-branched fatty acids. J Med Chem 1984;27:390-7.
33. Herrero P, Gropler RJ. Imaging of myocardial metabolism. J Nucl Cardiol 2005;12:345-58.
34. Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, et al. Metabolic imaging with/î-methyl-p-[123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005; 112:2169-74.
35. Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001;38:1888-94.
36. Mahmarian JJ. Myocardial metabolic imaging in the acute care setting. J Nucl Cardiol 2007;14:S139-44.
37. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol 2011;18:135-43.
38. Pastore CJ, Babich JW, Udelson JE. Future directions of myocardial fatty acid imaging. J Nucl Cardiol 2007;14: S153-63.
39. Tamaki N, Morita K, Kawai Y. The Japanese experience with metabolic imaging in the clinical setting. J Nucl Cardiol 2007;14:S145-52.
40. Le Guludec D, Lautamäki R, Knuuti J, Bax J, Bengel F. Present and future of clinical cardiovascular PET imaging in Europe: a position statement by the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging 2008;35:1709-24.
41. Kiran RN, Ben AD, Asim FC, Sirisha RN, Priya R, Ruth CC. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: a meta-analysis. Acad Radiol 2008;15:444-51.
42. Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF. Diagnostic emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol 2007;49:1052-8.
43. Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocar-dium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. J Nucl Med 2007;48:349-58.
44. Chow BJW, Wong JW, Yoshinaga K, Ruddy TD, Williams K, deKemp RA, et al. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. J Nucl Med 2005;46:1095-101.
45. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol 1977;80:865-70.
46. Yoshinaga K, Chow BJW, Williams K, Chen L, deKemp RA, Garrard L, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006;48:1029-39.
47. Knuuti J, Kajander S, Mäki M, Ukkonen H. Quantification of myocardial blood flow will reform the detection of CAD. J Nucl Cardiol 2009;16:497-506.
48. Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Prob Cardiol 2007;32:375-410.
49. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006;113:230-7.
50. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-Fluorodeoxyglucose positron emis-sion tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-12.
51. Merhige ME, Breen WJ, Shelton V, Houston T, D'Arcy BJ, Perna AF. Impact of myocardial perfusion imaging with PET and 82Rb on downstream invasive procedure utiliza-tion, costs, and outcomes in coronary disease management. J Nucl Med 2007;48:1069-76.
52. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomo-graphy, and coronary angiography for diagnosis of cor-onary artery disease. Circulation 1995;91:54-65.
53. Jacklin PB, Barrington SF, Roxburgh JC, Jackson G, Sariklis D, West PA, et al. Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. Ann Thorac Surg 2002;73:1403-9.
54. National Institute for Health and Clinical Excellence. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Tech-nology Appraisal 73. London, UK: NICE, 2003.